Send to

Choose Destination
Mol Pharm. 2016 Sep 6;13(9):2877-80. doi: 10.1021/acs.molpharmaceut.5b00775. Epub 2016 Feb 25.

Economic and Quality of Life Benefits of Anti-VEGF Therapy.

Author information

Shiley Eye Institute and Biomaterials and Tissue Engineering Center, Department of Ophthalmology and Institute for Engineering in Medicine, University of California, San Diego , La Jolla, California 92093, United States.
Department of Ophthalmology, Xijing Hospital, Fourth Military Medical University , Xi'an 710032, China.
Department of Ophthalmology, Shanghai First People's Hospital, School of Medicine, Shanghai JiaoTong University , Shanghai 20080, China.
Veterans Administration Healthcare System , San Diego, California 92093, United States.
Zhongshan Opthalmic Center, Sun Yat-sen University , Guangzhou 510060, China.


Vision impairment and blindness create a significant impact on quality of life and loss of productivity. Health care expenditures for vision problems, including direct medical costs and indirect costs for support services and loss of productivity, amount to $139 billion annually. It is projected that by 2020, five million people will have visual impairment due to age related macular degeneration and diabetic macular edema. VEGF inhibitor therapy has been shown to be a cost-effective treatment for age related macular degeneration and diabetic macular edema that has reduced the incidence of vision loss and can reduce the associated economic and societal cost.


QALY; VEGF; cost-effectiveness; diabetic macular edema; macular degeneration

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for American Chemical Society
Loading ...
Support Center